Airain ltd Takes $2.82 Million Position in Incyte Corporation (NASDAQ:INCY)

Marco Green
September 14, 2017

About 547,304 shares traded.

Having a price of $129.46, Incyte (NASDAQ:INCY) traded -1.30% lower on the day. It has outperformed by 56.14% the S&P500.

Global X Management Co Llc decreased Incyte Corp (INCY) stake by 41.23% reported in 2016Q4 SEC filing. The stock declined 2.83% or $3.67 reaching $125.79 per share. Vanguard Group Inc. now owns 15,415,857 shares of the biopharmaceutical company's stock worth $2,060,638,000 after buying an additional 2,847,907 shares in the last quarter. New Sr Invt Group Inc now has $751.66 million valuation. Next year this growth will reach 20.51% to attain $0.47. It has underperformed by 16.70% the S&P500. Therefore 45% are positive. Colliers had 11 analyst reports since August 6, 2015 according to SRatingsIntel. The stock has "Overweight" rating by Barclays Capital on Thursday, August 13. The stock of Colliers International Group Inc (NASDAQ:CIGI) earned "Outperform" rating by RBC Capital Markets on Wednesday, October 28. Jefferies has "Hold" rating and $145.0 target. Compass Point maintained it with "Buy" rating and $14 target in Friday, April 29 report. The firm has "Buy" rating given on Tuesday, August 2 by Wunderlich. The firm earned "Buy" rating on Wednesday, August 30 by Jefferies.

Investors sentiment increased to 1.37 in Q4 2016. NYRT has risen 0.73% in the 1-month period. It improved, as 32 investors sold INCY shares while 130 reduced holdings. 114 funds opened positions while 731 raised stakes. Tower Research Capital LLC TRC purchased a new position in Incyte Corporation during the first quarter worth about $105,000. Blackrock Group Incorporated has invested 0% in New Senior Investment Group Inc (NYSE:SNR). New York-based Valicenti Advisory Ser has invested 0.18% in Johnson & Johnson (NYSE:JNJ). Paloma Partners Mgmt Com reported 0.03% stake. Bank & Trust Of America De has 0% invested in New Senior Investment Group Inc (NYSE:SNR). The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.05) by $0.01. Northern Corporation holds 0.03% or 979,102 shares. Ghost Tree Capital Ltd Liability Com holds 0.31% or 13,000 shares in its portfolio. The firm owned 12,627 shares of the biopharmaceutical company's stock after selling 440 shares during the quarter. Gsa Llp accumulated 22,954 shares. Princeton Alpha Mngmt Limited Partnership owns 21,919 shares or 0.04% of their USA portfolio. Bnp Paribas Arbitrage Sa owns 127,677 shares. Xact Kapitalforvaltning AB now owns 27,196 shares of the biopharmaceutical company's stock worth $3,424,000 after acquiring an additional 556 shares in the last quarter. Abiomed Inc (NASDAQ:ABMD) was raised too.

Since March 16, 2017, it had 4 insider buys, and 13 sales for $25.81 million activity. 4,043 shares valued at $566,748 were sold by Siegel Eric H. on Monday, April 10. Huber Reid M sold 8,577 shares worth $1.02 million. 500 shares were bought by BIENAIME JEAN JACQUES, worth $62,130. The insider GRYSKA DAVID W sold $5.73M.

Incyte Corporation was covered by a number of analysts recently, 5 rated the stock as Buy, 3 rated Hold, 0 rated sell and 0 gave an Underperform. Therefore 87% are positive. The company has a consensus rating of "Buy" and an average target price of $114.47. Incyte had 63 analyst reports since August 6, 2015 according to SRatingsIntel. Incyte Corporation has a 52 week low of $77.58 and a 52 week high of $153.15. the firms market valuation is $25.28 B. Oppenheimer has "Hold" rating and $13500 target.

Wall Street brokerages predict that Incyte Corporation (NASDAQ:INCY) will post $0.02 earnings per share for the current fiscal quarter, Zacks reports. As per Tuesday, August 18, the company rating was maintained by Argus Research. BMO Capital Markets reaffirmed an "outperform" rating and set a $166.00 target price (up from $155.00) on shares of Incyte Corporation in a research note on Monday, June 5th. As per Friday, July 21, the company rating was maintained by BMO Capital Markets. As per Wednesday, March 23, the company rating was initiated by Morgan Stanley.

05/09/2017 - Incyte Corporation had its "outperform" rating reiterated by analysts at Credit Suisse. The rating was maintained by UBS with "Buy" on Wednesday, November 4. For the next year, analysts anticipate that the company will report earnings of $0.37 per share, with EPS estimates ranging from ($0.40) to $1.58. Brean Capital maintained Destination XL Group Inc (NASDAQ:DXLG) rating on Thursday, August 20.

Investors sentiment decreased to 1.02 in 2016 Q4. Its up 0.56, from 1.02 in 2016Q3. Of those insider trades, 143,895 shares of Incyte Corporation were purchased and 53,833 shares were sold. Commonwealth of Pennsylvania Public School Empls Retrmt SYS's holdings in Incyte Corporation were worth $1,590,000 at the end of the most recent reporting period.

Incyte Corporation (NASDAQ:INCY) last released its quarterly earnings results on Tuesday, August 1st.

About 3,309 shares traded. The California-based Reilly Financial Advsrs Limited Liability has invested 0.01% in Incyte Corporation (NASDAQ:INCY). Canada Pension Plan Investment Board boosted its stake in Incyte Corporation by 10.8% in the second quarter. Howe Rusling accumulated 0% or 266 shares. Senator Inv LP holds 300,000 shares. Ny State Common Retirement Fund invested 0.01% in WSFS Financial Corporation (NASDAQ:WSFS). Pnc Service invested in 0% or 1,265 shares. Strs Ohio reported 0% in Incyte Corporation (NASDAQ:INCY). Loral Space & Communications Ltd. (NASDAQ:LORL) has risen 8.44% since September 11, 2016 and is uptrending. Fort Washington Invest Oh invested in 0.01% or 6,902 shares. Driehaus Cap Mngmt Llc reported 23,524 shares.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER